SCHEMBL27166232

SCHEMBL27166232

COCCOCCOCCOc1ccc(C[C@H]2CNCCNCCNCCN2)cc1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.58
LTA4H P09960 1/20 0.47
SLC6A4 P31645 1/20 0.39
KDM4E B2RXH2 1/20 0.37
RECQL P46063 1/20 0.37
APP P05067 2/20 0.36
TDP1 Q9NUW8 1/20 0.35
REN P00797 1/20 0.34
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27166281 1.00 HRH3 (0.58) HRH3LTA4HSLC6A4KDM4ERECQL
SCHEMBL27268715 1.00 HRH3 (0.58) HRH3LTA4HSLC6A4KDM4ERECQL
SCHEMBL27166283 0.90 HRH3 (0.58) HRH3LTA4HKDM4ERECQLAPP
SCHEMBL27166248 0.90 HRH3 (0.58) HRH3LTA4HKDM4ERECQLAPP
SCHEMBL27166299 0.89 HRH3 (0.59) HRH3LTA4HTDP1RENMAOA
SCHEMBL27166279 0.84 HRH3 (0.66) HRH3LTA4HMAOAMAOB
SCHEMBL27166233 0.81 HRH3 (0.58) HRH3LTA4HTDP1MAOAMAOB
SCHEMBL27280958 0.80 HRH3 (0.55) HRH3LTA4HTDP1MAOA
SCHEMBL5367615 0.78 HRH3 (0.43) HRH3LTA4HSLC6A4KDM4EREN
SCHEMBL23477704 0.75 POLB (0.54) HRH3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077069-A1 COMBINATIONS OF CONTRAST AGENTS BAYER AG (DE) 2026-03-19 US disclosed
EP-4584251-A1 NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING Bayer Aktiengesellschaft (DE) 2025-07-16 EP disclosed
EP-4583925-A1 COMBINATIONS OF CONTRAST AGENTS Bayer Aktiengesellschaft (DE) 2025-07-16 EP disclosed
WO-2024052573-A1 COMBINATIONS OF CONTRAST AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2024-03-14 WO disclosed
WO-2024052573-A1 COMBINATIONS OF CONTRAST AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2024-03-14 WO disclosed
WO-2024052549-A1 NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING BAYER AKTIENGESELLSCHAFT (DE) 2024-03-14 WO disclosed
WO-2024052549-A1 NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING BAYER AKTIENGESELLSCHAFT (DE) 2024-03-14 WO disclosed
EP-4335461-A1 COMBINATIONS OF CONTRAST AGENTS Bayer AG (DE) 2024-03-13 EP disclosed
EP-4335840-A1 NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING Bayer Aktiengesellschaft (DE) 2024-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077069-A1 COMBINATIONS OF CONTRAST AGENTS GBA1, GBA3, GLS2 HRH3 587/4885LTA4H 2669/4885SLC6A4 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.